article thumbnail

How can Palantir win 'hearts and minds' to deliver the NHS England Federated Data Platform?

Lloyd Price

Overall, Palantir's software is helping to improve patient care, accelerate research, and improve drug development. Palantir's products are helping these organizations to improve patient care, accelerate research, and improve drug development. What are a few likely scenarios for Palantir in Healthcare?

article thumbnail

Palantir and Healthcare: What could the future hold?

Lloyd Price

Overall, Palantir's software is helping to improve patient care, accelerate research, and improve drug development. Palantir's products are helping these organizations to improve patient care, accelerate research, and improve drug development. What are a few likely scenarios for Palantir in Healthcare? Have a comment?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Medable Partners with Duke BASE Lab to Study Patient Preference of Electronic Informed Consent in Clinical Trials

Digital Health Global

the leading technology provider for modern clinical trials, announces results from a new research project with Duke University Department of Population Health Sciences’ Bioethics and Stakeholder (BASE) Lab on the acceptability of enhanced electronic informed consent (eIC) in clinical trials. .–(BUSINESS WIRE)–Medable Inc.,

article thumbnail

Medable Achieves 75% eConsent Adoption Across Elderly Patients in Pivotal U.S. Renal Care Clinical Trial

Digital Health Global

A Tufts Center for the Study of Drug Development study shows that, on average, decentralized trials can achieve net financial benefits from five to 13 times for Phase II and Phase III trials, equating to roughly $10 million ROI and $39 million ROI for an investment on average of $500K in Phase II and $1.5M

article thumbnail

Aviceda Therapeutics Announces Strategic Partnership with Queen’s University Belfast (QUB)

Digital Health Global

Aviceda Glycotech looks forward to this collaboration aimed at developing the next generation of cancer checkpoint immune therapeutics in Belfast. “It Co-Founder & President, and Chief Executive Officer. This commercial investment is testament to collaboration across the island of Ireland and the US.